According to reports, TRANSTHERA-B (02617) saw its shares surge by over 25%, and as of the time of writing, it is up 15.81% at HKD 200, with a trading volume of HKD 712 million. On the news front, TRANSTHERA announced via its official WeChat that on October 20, the company presented the latest consolidated research data on its core product, tegitnib, targeting cholangiocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting. Tegitnib is an innovative multi-target small molecule kinase inhibitor developed in-house, which exerts its anti-tumor effects by targeting tumor cells and improving the tumor microenvironment. Currently, tegitnib is undergoing multiple clinical trials in China and the U.S. for solid tumors, including cholangiocarcinoma, prostate cancer, and breast cancer. It has received Orphan Drug Designation (ODD) and Fast Track Designation from the U.S. FDA for cholangiocarcinoma treatment and Fast Track Designation for prostate cancer treatment, and was included in the list of breakthrough therapy products approved by China’s NMPA, along with receiving ODD from the European EMA for the treatment of biliary tract cancer.